Combined Biomarker Expression May Be Significant Driver of Tumorogenisis in Colorectum

Using immunohistochemistry to measure the expression of certain target enzymes —cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas.

Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news